From: Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
Endpoint | Local control | Lung PFS | Distant PFS | Overall survival | ||||
---|---|---|---|---|---|---|---|---|
Clinical variables | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
Primary histology (adeno vs other) | 0.52 (0.24–1.12) | 0.093 | 0.49 (0.27–0.87) | 0.023 | 0.73 (0.38–1.41) | 0.44 | 0.28 (0.12–0.67) | 0.009 |
Primary tumor site (lung vs other) | 1.94 (0.90–4.16) | 0.10 | 1.88 (1.06–3.33) | 0.043 | 1.66 (0.84–3.29) | 0.20 | 5.77 (2.39–13.94) | < 0.001 |
Primary tumor site (GI vs other) | 0.36 (0.15–0.90) | 0.029 | 0.66 (0.39–1.14) | 0.17 | 0.86 (0.45–1.64) | 0.77 | 0.24 (0.10–0.54) | 0.0015 |
Prior chemotherapy (yes vs no) | 3.25 (0.79–13.50) | 0.084 | 1.09 (0.59–2.02) | 0.90 | 0.96 (0.46–1.98) | 0.95 | 0.78 (0.31–2.01) | 0.79 |
Age > 65 (yes vs no) | 0.49 (0.21–1.14) | 0.090 | 0.94 (0.55–1.60) | 0.92 | 0.65 (0.34–1.24) | 0.25 | 0.95 (0.42–2.16) | 0.93 |
Performance status (1+ vs 0) | 3.63 (0.88–14.90) | 0.056 | 0.76 (0.40–1.46) | 0.52 | 2.10 (1.04–4.25) | 0.060 | 2.58 (1.01–6.58) | 0.082 |
Gender (male vs female) | 2.26 (0.94–5.44) | 0.060 | 0.93 (0.54–1.59) | 0.90 | 0.92 (0.49–1.72) | 0.92 | 0.85 (0.37–1.93) | 0.86 |